Archive

Category Archives for "股东权益"

Sichenzia Ross Ference LLP代表Aegis Capital进行460万美元的Medalist A股发行

medalist diversified reit logo

新闻稿-纽约州,纽约-2020年2月19日-Sichenzia Ross Ference LLP今天宣布,代表Aegis Capital Corp.作为独家簿记人参与200,000股8%发行的Medalist Diversified累积可赎回优先股的承销房地产投资信托基金REIT,Inc.(纳斯达克股票代码:MDRR),专门从事增值商业房地产的收购,所有权和管理。这些股票以每股23.00美元的发行价出售,总收益为460万美元,并开始在纳斯达克资本市场上交易,股票代码为“ MDRRP”。

continue reading >>

Sichenzia Ross Ference LLP代表ThinkEquity进行810万美元的配股和Duos Technologies普通股在纳斯达克上市

duostech logo

新闻稿-纽约,纽约-2020年2月18日-Sichenzia Ross Ference LLP今天宣布,其代表福特汉姆金融管理有限公司(Fordham Financial Management,Inc.)的子公司ThinkEquity为唯一的账簿管理人,而基准公司(The Benchmark Company)为该公司的联合经理。以每股6.00美元的价格发行810万美元的Duos Technologies Group,Inc.(NASDAQ:DUOT)的普通股。发行同时,普通股获准在纳斯达克资本市场上市,并于2020年2月13日开始交易,股票代码为DUOT。

continue reading >>

Sichenzia Ross Ference LLP代表Aegis Capital进行450万美元的Avinger,Inc.普通股的后续发行

avinger logo

新闻稿-纽约州,纽约-2020年2月4日-Sichenzia Ross Ference LLP今天宣布代表Aegis Capital Corp.作为独家簿记人,参与后续发行Avinger,Inc.(NASDAQ)6,428,572股普通股:AVGR),领先的外周动脉疾病治疗方法开发商,发行价为每股0.70美元,总收益为450万美元。根据Avinger在表格S-1上的有效注册声明(注册号333-235902)发售和出售股票。

continue reading >>

Sichenzia Ross Ference LLP代表匈牙利风险投资公司HiVentures Zrt。私下配售ActiveGraf的A股优先股

activegraf logo

新闻稿-纽约,纽约-2020年1月16日-Sichenzia Ross Ference LLP今天宣布代表匈牙利投资公司MFBNövekedésiTökealap及其经理,致力于推广的国有风险投资公司Hiventures Zrt。代表匈牙利的初创企业和企业购买了ActiveGraf Inc.的约90万美元A股优先股,ActiveGraf是北卡罗来纳州的一家私营公司,致力于创建交互式数据分析。

continue reading >>

Sichenzia Ross Ference LLP代表A.G.P./Alliance Global Partners作为独家配售代理处理Cellect Biotechnology Ltd.以300万美元注册直接发行。

cellect logo

新闻稿–纽约,纽约– 2020年1月10日– Sichenzia Ross Ference LLP今天宣布代表AGP / Alliance Global Partners作为独家配售代理以Cellect Biotechnology Ltd的登记直接发行1,000,000美国存托股份(“ ADS”) (纳斯达克股票代码:“ APOP”),这是一种创新技术的开发商,能够对干细胞进行功能选择。每个ADS代表APOP的100股普通股。发行价格为每ADS 3.00美元,总收益约为3,000,000美元,扣除费用和其他估计发行费用。

continue reading >>

Sichenzia Ross Ference LLP代表Beyond Air,Inc.进行1150万美元的承销普通股和并行私募的公开发行

beyond air logo

新闻稿-纽约州,纽约-2019年12月12日-Sichenzia Ross Ference LLP今天宣布代表Beyond Air,Inc.(NASDAQ:XAIR),一家专注于开发可吸入一氧化氮(NO)的临床阶段医疗器械和生物制药公司。为治疗严重的呼吸道疾病,以每股3.66美元的价格成功完成了承销的公开发行和并发私募的约1150万美元的Beyond Air普通股。公开发行是根据向证券交易委员会提交的有效货架注册声明进行的。私募股份不会被注册。

continue reading >>

Sichenzia Ross Ference LLP代表Relmada Therapeutics,Inc.进行1.15亿美元的承销普通股公开发行

relmada

新闻稿-纽约州,纽约-2019年12月6日-Sichenzia Ross Ference LLP今天宣布代表Relmada Therapeutics,Inc.(纳斯达克股票代码:RLMD)(一家开发抑郁症和中枢神经系统疾病疗法的临床阶段公司)成功完成以每股30.00美元的价格承销300万股Relmada普通股的公开发售。

continue reading >>

Sichenzia Ross Ference LLP代表Aegis Capital Corp.完成对Cocrystal Pharma,Inc. 300万美元普通股的公开发行。

co crystal pharma inc

新闻稿-纽约州,纽约-2019年11月4日-Sichenzia Ross Ference LLP今天宣布代表Aegis Capital Corp.作为独家承销商参与Cocrystal Pharma,Inc.(NASDAQ:COCP)3,529,412股的承销公开发行。普通股,每股价格为0.85美元,总收益约为300万美元。 Cocrystal是一家临床阶段生物技术公司,致力于发现和开发新型抗病毒疗法 continue reading >>

Sichenzia Ross Ference代表Pareteum Corporation进行4000万美元的普通股和认股权证发行

The Sichenzia Ross Ference LLP team was led by partners Darrin M. Ocasio and Avital,  Perlman, Counsel Jeffrey Cahlon and associate Grant Levine.

新闻稿-纽约,纽约-2019年9月27日-全国公认的证券和公司律师事务所Sichenzia Ross Ference LLP今天宣布,其代表全球云软件通信平台公司Pareteum Corporation(Nasdaq:“ TEUM”)承销公开发行18,852,273股普通股,每个单位由TEUM普通股的一股,一份购买TEUM普通股的A系列的购买权证,以及购买TEUM普通股的一半的B系列购买权证,以及3,875,000个预基金单位,包括一份预购权证,用于购买TEUM普通股的一股;一份A系列购买权证,用于购买TEUM普通股的一股; B系列购买权证,用于购买TEUM的一半股本。普通股。

continue reading >>

Sichenzia Ross Ference LLP代表Aegis Capital以450万美元公开发售Avinger,Inc。普通股

avinger logo

新闻稿 – 纽约州纽约市 –  2019年8月26日 – Sichenzia Ross Ference LLP今天宣布,它已代表Aegis Capital Corp.作为公开发行股票的唯一账簿管理人,共同出售3,813,559股Avinger,Inc。(纳斯达克股票代码:AVGR)股票股票,每股1.18美元,总收益约为450万美元。 Avinger是外周动脉疾病创新治疗的领先开发商

continue reading >>

Sichenzia Ross Ference LLP代表Aegis Capital Corp.以230万美元公开发行Sigma Labs,Inc。的普通股

sigma labs logo

新闻稿 – 纽约,纽约 –  2019年8月2日 – Sichenzia Ross Ference LLP今天宣布,它已代表Aegis Capital Corp.作为Sigma Labs,Inc。的287.5万股普通股的承销公开发行的唯一账面管理经理。纳斯达克股票代码:SGLB)每股收益0.80美元,总收益为230万美元。 Sigma Labs是PrintRite3D品牌下的质量保证软件提供商。

continue reading >>

Sichenzia Ross Ference LLP代表ThinkEquity以135万美元的方式公开发行Immuron Limited的ADS

immuron logo

新闻稿 – 纽约,纽约 –  2019年7月23日 – Sichenzia Ross Ference LLP今天宣布,它代表福特汉姆财务管理部门ThinkEquity作为Immuron Limited(纳斯达克证券交易所股票代码制品公司)135万美元公开募股的唯一账簿管理人“IMRN”ASX。“IMC”)。此次发行包括339,130​​股ADS,每股ADS收费4.00美元,总收益为135万美元。 Immuron是一家专注于口服免疫球蛋白疗法的澳大利亚生物制药公司。 Sichenzia Ross Ference团队由Partners Gregory Sichenzia和Tara Guarneri-Ferrara领导。

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP代表RealWear,Inc。进行了8,000万美元的融资交易

realwear inc logo

新闻稿 –  2019年7月9日 – 纽约州纽约 –  Sichenzia Ross Ference LLP代表RealWear,Inc。,一家创新科技公司,其旗舰产品HMT-1®是第一款坚固耐用的头戴式,可穿戴式,Android级平板电脑,可以解雇工人手中的危险工作,融资交易筹集了8000万美元。 B轮融资由Teradyne,Inc。(TER)领导,Teradyne,Inc。是工业自动化领域的全球领导者,其中包括Qualcomm Ventures和Bose Ventures等其他行业领导者的参与。 JPMorgan Chase&Co。担任RealWear,Inc。与B系列融资的独家配售代理。

continue reading >>

Sichenzia Ross Ference LLP代表Vuzix Corporation以2000万美元注册直接发行

vuzix

新闻稿 – 纽约州纽约市 –  2019年7月8日 – Sichenzia Ross Ference LLP今天宣布,它代表Vuzix公司(纳斯达克“VUZI”)在注册直接公开发行股票,注册股票约548万股,价格为每股3.65美元和约548万股普通股购买认股权证,每股行使价4.10美元,对Vuzix的总收益约为2,000万美元。特别股权集团是Bradley Woods&Co。Ltd.的一个部门,是该发行的独家代理商。 Sichenzia Ross Ference LLP团队由Partners Gregory Sichenzia,Tara Guarneri-Ferrara和顾问Jeff Cahlon领导。

Sichenzia Ross Ference LLP以560万美元的普通股公开发行代理文件安全系统公司

document security systems logo

Press Release – New York, NY – June 10, 2019 – Sichenzia Ross Ference LLP announced today that it has represented its client, Document Security Systems, Inc. (NYSE American: DSS), in a $5.6 million public offering of its common stock.  The offering consisted of 11.2 million shares of common stock at a price of $0.50 per share. Aegis Capital Corp. served as sole book running manager in connection with the offering. DSS is a leader in the anti-counterfeit, authentication and diversion protection technology space. The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia, Darrin Ocasio, Tara Guarneri-Ferrara and Jeffrey D’Angelo.

Sichenzia Ross Ference LLP代表Medicine Man Technologies,Inc。提供高达1400万美元的私人配售

medicine man technologies

Press Release – New York, NY – June 10, 2019 – Sichenzia Ross Ference LLP announced today that it has represented Medicine Man Technologies, Inc. (OTC: MDCL) (“Medicine Man or the “Company”) in a securities purchase agreement with Dye Capital & Co. for the sale of up to $14 million of shares and common stock purchase warrants of the Company. The shares were sold at a price of $2.00 per share.

continue reading >>

Sichenzia Ross Ference LLP宣布以130万美元私募配售Medivist Diversited REIT,Inc。

medalist diversified logo

Press Release – New York, NY – May 31, 2019 –  Sichenzia Ross Ference LLP announced today that it has represented Aegis Capital Corp. as placement agent in a private offering of 270,833 shares of Common Stock of Medalist Diversified REIT, Inc. (NASDAQ: MDRR) at a purchase price of $4.80 per share for gross proceeds of approximately $1.3 million.

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents ToughBuilt Industries, Inc. in $6.1 Million Private Offering

toughbuilt logo

Press Release – New York, NY – October 18, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented ToughBuilt Industries, Inc. (“ToughBuilt”) in a private placement of equity as well as debt securities.  ToughBuilt is a private company that markets and distributes various home improvement and construction product lines for both do-it-yourself and professional markets under the TOUGHBUILT® brand name within the global multi-billion dollar per year tool market industry.

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents Laidlaw & Company (UK) Ltd. as Placement Agent for a $3 Million Private Placement

fte networks logo

Press Release – New York, NY – October 17, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Laidlaw & Company (UK) Ltd. as the exclusive placement agent in a private placement of equity securities of FTE Networks, Inc. (OTCQX: FTNW), continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement

aridis

PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.  Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering.  The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.

Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw as Exclusive Placement Agent for a $3.77 Registered Direct Offering

eyegate pharma logo

Press Release – New York, NY – July 11, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Rodman & Renshaw, a unit of H.C. Wainwright& Co., LLC, as the exclusive placement agent for a registered direct offering of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye (“EyeGate”).

continue reading >>

Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock

tonix pharmaceuticals

Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Represents Joseph Gunnar in $2.1 Million Public Offering of Intellicheck Mobilisa, Inc.

intellicheck logo

Press Release – New York, NY – June 21, 2016 – Nationally recognized securities and corporate law firm, Sichenzia Ross Friedman Ference LLP, announced today that it has represented Joseph Gunnar & Co. LLC as sole book-running manager in a firm commitment underwritten public offering of shares and warrants of Intellicheck Mobilisa, Inc.

continue reading >>

Partners Richard A. Friedman and Stephen A. Cohen Represent Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book Running Managers of PhaseRx, Inc.’s $18.5M IPO

phase rx

Press Release – New York, NY – May 23, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book-Running Managers of the initial public offering of PhaseRx, Inc. (NASDAQ: PZRX).

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Axiom Capital Management, Inc. In $1.2 Million Public Offering of iSign Solutions Inc.

isign

Press Release – New York, NY – May 19, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Axiom Capital Management, Inc. as the underwriter in a firm commitment underwritten public offering of equity securities of iSign Solutions Inc.

The offering consisted of 690,000 shares of common stock and warrants to purchase up to 345,000 shares of common stock. The common stock and warrants were offered at prices to the public of $1.74 and $0.01, respectively. The common stock and warrants trade under the symbols “ISGN” and “ISGW”, respectively. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Richard Friedman, David Manno and associate Jeff Cahlon.

Sichenzia Ross Friedman Ference LLP Represents Viatar CTC Solutions Inc. in a $4.2 Million Private Placement

viatar

Press Release – New York, NY – March 3, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Viatar CTC Solutions Inc., a medical technology company focused on the treatment of patients with metastatic cancer, in a private placement of $4.2 million of Series B Preferred Stock. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Laidlaw & Company (UK) Ltd. as Placement Agent for a $6.9 Million Private Placement

pershing gold

Press Release – New York, NY – February 26, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Laidlaw & Company (UK) Ltd. as the exclusive placement agent in a private placement of equity securities of Pershing Gold Corporation (NASDAQ: PGLC), a mining company (the “Company”). In connection with the offering, the Company accepted subscriptions for the sale of approximately $6.9 million in gross proceeds of 2,120,882 Units, with each Unit comprised of 1 share of Common Stock and a 30 month warrant to acquire 0.5 of a share of Common Stock at an exercise price of $5.06, at a price of $3.25 per Unit.

continue reading >>

Partners Darrin Ocasio and Arthur Marcus Represent CBC Biotechnologies Inc. in Series A Preferred Stock Venture Financing

cbc biotechnologies

Press Release – New York, NY – December 24, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that the firm has represented CBC Biotechnologies Inc., a commercial solutions provider of cannabinoid based products with applications in the fields of pharmaceuticals, nutraceuticals and cosmetics/skin care, in connection with a $2,000,000 Series A venture financing with Tuatara Capital Fund I, L.P.
continue reading >>

Partner Richard Friedman Represents eMagin Corporation in $6M Registered Direct Offering

eMagin

Press Release – New York, NY – December 23, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm has represented eMagin Corporation (NYSE MKT: EMAN) (the “Company”), the leader in the development, design and manufacture of Active Matrix OLED microdisplays for high resolution imaging products, in connection with its $6,000,000 registered direct offering. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Takung Art Co., LTD on $1.58M PIPE

Takung

Press Release – New York, NY – November 17, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that the Firm has represented Takung Art Co., a provider of an online platform for artists and creative professionals, in connection with a $1,580,000 private placement of the Company’s common stock priced at $1.58 per share.
continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Oasmia Pharmaceutical AB on $9.5M IPO and U.S NASDAQ listing

oasmia

SRFF LLP Advises Fifth Swedish IPO on U.S. NASDAQ

October 28, 2015 – Press Release – New York, NY –Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today the Firm has represented Oasmia Pharmaceutical AB (NASDAQ: OASM) (NASDAQ Stockholm: OSAM.ST), a Swedish biopharmaceutical company focused on developing innovative treatments within human and animal oncology, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at an offering price of $4.06 per ADS. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Israeli Biotech Company Can-Fite Biopharma on $4.8M Registered Direct Offering of ADSs

can-fite biopharma

New York, NY – Press Release – October 15, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today that the Firm has represented Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), an Israeli biotechnology company advancing a pipeline of proprietary small molecule drugs that addresses cancer and inflammatory diseases, on a registered direct offering with institutional investors where the Company issued 1,109,196 American Depository Shares (ADSs) at a purchase price of $4.35 per ADS. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents ContraVir Pharmaceuticals, Inc. on $15 Million Public Offering of Common Stock and Warrants

contravir

Press Release – New York, NY – October 14, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical  company focused on the development and commercialization of targeted antiviral therapies, on an underwritten public offering of 5,000,000 shares of the Company’s common stock and warrants to purchase up to 3,000,000 shares of common stock at a combined public offering price of $3.00. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Rightscorp in $1.032M PIPE

rightscorp

October 9, 2015 – New York, NY – Press Release – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Rightscorp, Inc., a technology company that provides monetization services for holders of copyrighted intellectual property (OTCQB:RIHT) in a private placement offering where the Company sold to accredited investors 10,320,000 shares of common stock and warrants.
continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in $5.5M Registered Direct Offering and Private Placement

amarantus bioscience

October 1, 2015 — New York, NY – Press Release – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) is pleased to announce that the Firm has represented Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan indications and neurology in a registered direct offering where Amarantus issued $2.75 million of newly designated Series H convertible preferred stock and warrants. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Israeli Company Can-Fite BioPharma on $9.0M Public Offering of ADSs

can-fite biopharma

New York, NY – Press Release – September 22, 2015 –Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Israeli biotechnology company, Can-Fite BioPharma (NYSE: CANF)(TASE: CFBI) on a public offering with institutional investors where Can-Fite received $9 million in gross proceeds. continue reading >>

Sichenzia Ross Friedman Ference LLP Advises Underwriter Aegis Capital on U.S. Initial Public Offering of Israeli Biopharmaceutical Company

biondvax pharmaceuticals

Represents first Israeli-American collaborative transaction between affiliated law firms SRFF LLP and DTKGC & Co.

New York, NY – May 15, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today that the Firm has represented the underwriter Aegis Capital Corp. on the U.S. initial public offering of BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), continue reading >>

Sichenzia Ross Friedman Ference LLP 代表以色列的 Wellsense 开展 2 百万美元的私募

wellsense

新闻稿纽约州纽约 – 2015 年 7 月 1 日 – 总部设在纽约的证券与企业法律师事务所 Sichenzia Ross Friedman Ference LLP (“SRFF”) 今日宣布该事务所已经代表 Enhanced Surface Dynamics Inc. D.B.A Wellsense USA(以色列设计的褥疮监控设备的生产公司)进行该公司优先股和认股权证的 2 百万美元私募

WellsenseProfiscope Campus 开发。Profiscope Campus 是以色列科技孵化园,由 Powermat Technologies 创始人 Ran Poliakine 创办。Wellsense 的专利 M.A.P. 系统使用持续床边压力技术,使看护人能够使用实时压力分布数据监控患者。Sichenzia Ross Friedman Ference LLP 的团队由合伙人 Gregory Sichenzia、法律顾问 Peter DiCharia 及 Gary Emmanuel 领导。National Securities Corporation 作为此次发行的私募代理商。

关于 Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP 是一家总部设在纽约市的律师事务所,提供证券行业各类事务的律师代理业务。他们的律师擅长为客户提供建议,例如私募、首次公开发行 (IPO)、第二次公开 发行、替代性出版发行、编制 SEC 备案文件以及在主要资本股票交易所上市,例如纽约证券交易所、NASDAQ 和 OTC 市场此外,该事务所的诉讼和仲裁律师技术娴熟,擅长代表客户在 SEC、FINRA 及其他监管机构出庭进行常规诉讼或复杂案件诉讼。SRFF 在欧洲有国际合作机构,也擅长向国外发行商提供美国 IPO 和公开发行方面的建议。欲知详情,请访问 www.srff.com 以及在 twitter 上关注 SRFF,账号 @srffllp

Sichenzia Ross Friedman Ference LLP 代表 LaidLaw & Company (UK) 有限公司完成 Actinium Pharmaceuticals 公司的500 万美元注册直接发行

actinium pharmaceuticals

2015 6 18 纽约州纽约位于纽约的证券和公司律师事务所 Sichenzia Ross Friedman Ference LLP (“SRFF”) 今日宣布该事务所已经代表唯一配售代理 Laidlaw & Company (UK) 完成了 Actinium Pharmaceuticals 公司 (NYSE MKTATNM)(一家为治疗晚期癌症开发创新靶向免疫疗方法的生物制药公司)的注册直接发行。发行包括以每股2.60 美元的购买价发行的 1,923,078 股公司普通股,累计总收益约为5,000,000 美元。

Sichenzia Ross Friedman Ference LLP 团队由合伙人 Richard A. Friedman Stephen A. Cohen 领导

关于 Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP 是一家位于纽约的律师事务所,就涉证券行业的众多事务提供经验丰富的代理。他们的律师专门就私募配售、首次 (IPO) 和二次公开募股、替代性公开发售、编制 SEC 文件和在 NYSE纽约证券交易所)、NASDAQ OTC 场等主要资本股票交易所上市为客户提供建议。此外,该事务所的诉讼和仲裁律师在代表客户面对 SECFINRA 和其他监管机构处理从日常诉讼到复杂案例的业务方面非常熟练。SRFF 在欧洲也有国际附属公司,同样专门为外国发行商就美国 IPO 和公开发行提供建议。若要了解更多信息,请访问 www.srff.com 并在 twitter @srffllp 上关注 SRFF

主页 > 新闻 > Vuzix 公司宣布来自 Intel 的$248万美元投资

vuzix

Vuzix 公司宣布来自 Intel $2480 万美元投资

Sichenzia Ross Friedman Ference LLP 代表Vuzix 公司处理来自 Intel $2480 万美元的投资事宜

纽约州纽约市2015 1 5 日)位于纽约的证券和企业律师事务所 Sichenzia Ross Friedman Ference LLP 今日宣布该事务所代表 Vuzix® 公司 (OTCQB:VUZI)Vuzix公司——一家视频眼镜和智能眼镜产品的领先供应商——执行一次投资交易,在这次交易中 Intel 公司对 Vuzix 投资 $2480 万美元。Intel 的投资将用于日常流动资金,并会有助于加速引进 Vuzix 下一代可穿戴显示器产品进入消费者市场

Intel 购买了 49,626 Vuzix A 系列优先股,可按照每股 $5.00美元的初始转换价转换为 4,962,600 股该公司的普通股。在转换 A 系列优先股时可以发行的股份占到 Vuzix 流通股约 30%

Sichenzia Ross Friedman Ference LLP 团队由合伙人 Gregory SichenziaThomas A. RoseTara Guarneri Ferrara 和合伙人 Jeffrey Cahlon 领导

关于 Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP 是一家证券和企业律师事务所,它提供经验丰富的专业代表处理涉及证券行业的所有事务,以及所有一般企业事务和诉讼事务。该事务所的客户既有初创公司也有著名的上市公司,包括私营和上市企业、合伙企业、券商、银行下属券商、投资顾问、注册工作人员、政府和企业客户和投资者、合作伙伴以及其他实体。该事务所也就包括复杂证券法考虑事项在内的交易为机构投资者提供建议,其业务包括作为美国以及世界各地的客户的代表。要了解关于 Sichenzia Ross Friedman Ference LLP 的更多信息,请访问 SRFF LinkedIn SRFF Twitter@SRFFLLP

PlasmaTech Announces $14.0 M Public Offering and NASDAQ Listing

plasmatech biopharmaceuticals

New York, NY – December 24, 2014 – Press Release: New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm  represented H.C. Wainwright & Co. and Aegis Capital Corp. as underwriters in PlasmaTech Biopharmaceuticals, Inc.’s public offering of 3,500,000 shares of common stock and 3,500,000 warrants. The gross proceeds from the offering were $14,035,000 and the offering price was $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00 and are exercisable immediately.  PlasmaTech common stock and warrants began trading on the NASDAQ Capital Market (effective December 19, 2014) under the symbols “PTBI” and “PTBIW” respectively.

PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advanced targeted treatments for critical patient care. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.

Sichenzia Ross Ference LLP

 

Can-Fite Biopharma Ltd. Announces $8.0 M At-The-Market Registered Direct Offering

can-fite biopharma

Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharma Ltd. On A $8.0 M At-The-Market Registered Direct Offering

New York, NY – (Global Newswire) – 12/20/2014 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Israeli biopharmaceutical company, Can-Fite Biopharma Ltd. (TASE: CFBI; NYSE MKT: CANF) on an at-the-market registered direct offering of for gross proceeds of $8,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partner Gregory Sichenzia, Associates Gary Emmanuel and Avital Even-Shoshan. H.C. Wainwright & Co., LLC acted as the Placement Agent in the offering.

Sichenzia Ross Ference LLP

ContraVir Pharmaceuticals Announces $9.0 Million Private Placement

contravir

Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement

New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.

Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.

Sichenzia Ross Ference LLP

CEL-SCI Corporation Announces $6.0 Million Public Offering

cel sci

Sichenzia Ross Friedman Ference LLP Represents CEL-SCI Corporation on $6.0 Million Public Offering

New York, NY – October 29, 2014 – GLOBAL NEWSWIRE – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it has advised Laidlaw & Co. (UK) Ltd. as the Lead Underwriter in a $6 million public Public Offering of CEL-SCI Corporation (NYSE MKT: CVM), a late-stage biotechnology company focused on oncology research and drug development. The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of common stock and warrants at a combined price of $0.76 per unit. Pursuant to the offering, CEL-SCI issued one warrant to purchase common stock for every four shares sold. The warrants have an exercise price of $1.25 per unit. The Sichenzia Ross Friedman Ference LLP team was led by Partner Richard A. Friedman and Associate Stephen Cohen.

Sichenzia Ross Ference LLP

 

Sichenzia Ross Friedman Ference LLP Advises Labor Smart, Inc. on a $1.1 million Private Placement of Common Stock.

laborsmart

August 18, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Labor Smart, Inc. (OTCBB: LTNC), a provider of on-demand construction, manufacturing and retail staffing , in a $1.1 million private placement pursuant of Regulation D. The transaction consisted of original issue discount debentures convertible at $0.15 per share and 100,000 shares of common stock. The Sichenzia RossFriedman Ference LLP  team was led by Gregory Sichenzia and Jeff Cahlon.

Sichenzia Ross Ference LLP

 

Sichenzia Ross Friedman Ference LLP Advises J.P. Turner & Company, L.L.C on $ 2.5 million Private Placement of X2 Bio Systems, Inc..

xz biosystems

NEW YORK, April 18, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented J.P. Turner & Company as sole Placement Agent in a $2.5 million private placement of X2 Bio systems, Inc., a privately held Seattle based science and technology company which is developing the first complete solution for assessing sport brain injuries. The offering consisted of $2.5 million of Units consisting of 6% convertible promissory notes and common stock purchase warrants. The Sichenzia Ross Friedman Ference LLP team was led by partners Gregory Sichenzia and David Manno.

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Medovex Corp. Announces $8.0 M IPO

medovex corp

Sichenzia Ross Friedman Ference LLP Represents Medovex Corp. in $ 8.0M Initial Public Offering

New York, NY – December 29, 2014 – Global Medovex NasdaqNewswire – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that the Firm has represented Medovex Corporation (NASDAQ: MDVXU), a producer of medical device products, in an initial public offering of 1,391,305 units. Each unit consisted of one share of common stock and one Series A Warrant at a price of $5.75 per unit. The IPO resulted in gross proceeds of $8,000,003 to the Company. The IPO was underwritten by Laidlaw & Company (UK) LTD.

The units trade on the NASDAQ Capital Markets under the symbol “MDVXU” and the common stock and warrants will trade under the symbols “MDVX” and “MDVXW”, respectively on separation.

Medovex is developing and commercializing the DenerVex® device, which is used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. In 2013, Medovex entered into a Co-Development Agreement with Dr. James Andrews, a renowned orthopedic surgeon who also is a director of the Company. Additionally Medovex intends to seek out acquisition opportunities through its world class Board of Directors which also includes Steve Gorlin, Major General C.A. “Lou” Hennies and Dr. Scott M. W. Haufe.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Harvey Kesner, Arthur S. Marcus and Associate Marc J. Adesso.

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Acted as Lead Investor Counsel on VBI Vaccines’ $5.25 million private placement

Securities Law Firm | Sichenzia Ross Friedman Ference LLP

NEW YORK, August 1, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announces that it represented the lead investor in a $5.25 million private placement conducted by VBI Vaccines Inc. (NASDAQ: VBIV), formerly Paulson Capital (Delaware) Corp. The offering, which originally closed into escrow on July 25, 2013, consisted of the sale of one unit of VBI’s securities, made up of shares of Common Stock, Series A Preferred Stock and two class of warrants exercisable into shares of VBI’s Series B Preferred Stock. The release of the funds and securities in escrow was subject to certain conditions precedent which was satisfied on July 25, 2014, at which time the funds and securities were released.

VBI Vaccines, Inc. is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The Sichenzia Ross Friedman Ference LLP team was led by partner Harvey Kesner and associate Tara Guarneri-Ferrara.

Media Contact
pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Conkwest, Inc. on $7.06 million Private Placement of Units consisting of Series C Convertible Preferred Stock and Warrants to Purchase Common Stock.

conkwest

NEW YORK, April 11, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Conkwest, Inc. in a $7.06 million private placement of the Preferred Stock and Warrants of Conkwest, Inc., a privately held company which is involved in the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell-lines. The private placement was pursuant to Rule 506 of Regulation D. The offering consisted of 2,943,698 Units consisting of 2,943,698 shares of Series C Preferred Stock and 735,924 warrants to purchase common stock shares at $2.40 per Unit for a total offering of $7,064,875. Palladium Capital Corp. acted as placement agent on the offering. The Sichenzia Ross Friedman Ference LLP teamwas led by partners Harvey Kesner and Arthur S. Marcus.

 

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Spherix Incorporated on $4.4 million PIPE Offering

spherix intellectual property

NEW YORK, March 26, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Spherix Incorporated (SPEX. NASDAQ) on a $4.4 million private placement of units consisting of Common Stock and warrants at a unit price of $3.75. Spherix is an intellectual property company that owns patented and unpatented intellectual property. Laidlaw & Company (UK) Ltd. as sole placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by partners Harvey Kesner and associate Tara Guarneri-Ferrara.

 

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP